Citius Pharmaceuticals, Inc.CTXRNASDAQ
Loading
Year-over-year earnings per share growth rate
3Y CAGR
-37.2%/yr
vs +69.0%/yr prior
Acceleration
-106.2pp
Decelerating
Percentile
P62
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.64% |
| Q3 2025 | 45.00% |
| Q2 2025 | 37.01% |
| Q1 2025 | 2.31% |
| Q4 2024 | 18.24% |
| Q3 2024 | -1.27% |
| Q2 2024 | -17.16% |
| Q1 2024 | 7.59% |
| Q4 2023 | -2216.29% |
| Q3 2023 | -13.61% |
| Q2 2023 | 23.47% |
| Q1 2023 | -192.68% |
| Q4 2022 | 55.03% |
| Q3 2022 | 9.29% |
| Q2 2022 | -16.86% |
| Q1 2022 | 18.35% |
| Q4 2021 | -85.88% |
| Q3 2021 | 20.00% |
| Q2 2021 | 0.93% |
| Q1 2021 | 71.40% |
| Q4 2020 | -36.36% |
| Q3 2020 | 0.00% |
| Q2 2020 | 15.38% |
| Q1 2020 | 13.33% |
| Q4 2019 | 16.67% |
| Q3 2019 | 10.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 9.09% |
| Q4 2018 | 18.52% |
| Q3 2018 | -42.11% |
| Q2 2018 | 56.82% |
| Q1 2018 | -15.79% |
| Q4 2017 | 32.14% |
| Q3 2017 | -16.67% |
| Q2 2017 | 12.73% |
| Q1 2017 | -25.00% |
| Q4 2016 | 38.03% |
| Q3 2016 | 5.33% |
| Q2 2016 | -114.29% |
| Q1 2016 | 33.96% |